Pirker R - Search Results

1

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.

Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R; European EGFR Workshop Group. Pirker R, et al. J Thorac Oncol. 2010 Oct;5(10):1706-13. doi: 10.1097/JTO.0b013e3181f1c8de. J Thorac Oncol. 2010. PMID: 20871269 Free article.

2

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC).

Pirker R, Krajnik G, Zöchbauer S, Malayeri R, Kneussl M, Huber H. Pirker R, et al. Ann Oncol. 1995 Oct;6(8):833-5. doi: 10.1093/oxfordjournals.annonc.a059324. Ann Oncol. 1995. PMID: 8589023 Free article. Clinical Trial.

3

Clinical relevance of drug resistance genes in malignant disease.

Filipits M, Suchomel RW, Zöchbauer S, Malayeri R, Pirker R. Filipits M, et al. Among authors: pirker r. Leukemia. 1996 Jul;10 Suppl 3:S10-S17. Leukemia. 1996. PMID: 8656694 Review.

4

Multidrug resistance in leukemias and its reversal.

Malayeri R, Filipits M, Suchomel RW, Zöchbauer S, Lechner K, Pirker R. Malayeri R, et al. Among authors: pirker r. Leuk Lymphoma. 1996 Nov;23(5-6):451-8. doi: 10.3109/10428199609054853. Leuk Lymphoma. 1996. PMID: 9031075 Review.

5

Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status.

Filipits M, Suchomel RW, Lechner K, Pirker R. Filipits M, et al. Among authors: pirker r. Leukemia. 1997 Jul;11(7):1073-7. doi: 10.1038/sj.leu.2400655. Leukemia. 1997. PMID: 9204994

6

Phase II trial of gemcitabine in advanced non-small-cell lung cancer.

Malayeri R, Ulsperger E, Baumgartner G, Forstner B, Aigner K, Hubner M, Kummer F, Krajnik G, Zöchbauer S, Krejcy K, Huber H, Pirker R. Malayeri R, et al. Among authors: pirker r. Wien Klin Wochenschr. 1997 Sep 19;109(17):688-91. Wien Klin Wochenschr. 1997. PMID: 9331958 Clinical Trial.

7

Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia.

Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner K, Pirker R. Filipits M, et al. Among authors: pirker r. Blood. 1998 Mar 1;91(5):1508-13. Blood. 1998. PMID: 9473213 Free article.

8

Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.

Filipits M, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R. Filipits M, et al. Among authors: pirker r. Clin Cancer Res. 1997 Aug;3(8):1419-25. Clin Cancer Res. 1997. PMID: 9815827 Clinical Trial.

9

MRP and MDR1 gene expression in primary breast carcinomas.

Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D, Pirker R. Filipits M, et al. Among authors: pirker r. Clin Cancer Res. 1996 Jul;2(7):1231-7. Clin Cancer Res. 1996. PMID: 9816292

10

Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.

Krajnik G, Wein W, Greil R, Marhold F, Mohn-Staudner A, Kummer F, Malayeri R, Zöchbauer-Müller S, Huber H, Pirker R. Krajnik G, et al. Among authors: pirker r. Eur J Cancer. 1998 Nov;34(12):1977-80. doi: 10.1016/s0959-8049(98)00235-4. Eur J Cancer. 1998. PMID: 10023326 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

227 results

Search Page